Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia

Summary

Streptococcus (S.) pneumoniae is the most common causative pathogen in community-acquired pneumonia. Coagulation and inflammation interact in the host response to infection. Tissue factor pathway inhibitor (TFPI) is a natural anticoagulant protein that inhibits tissue factor (TF), the main activator of inflammation-induced coagulation. It was the objective of this study to investigate the effect of endogenous TFPI levels on coagulation, inflammation and bacterial growth during S. pneumoniae pneumonia in mice. The effect of low endogenous TFPI levels was studied by administration of a neutralising anti-TFPI antibody to wild-type mice, and by using genetically modified mice expressing low levels of TFPI, due to a genetic deletion of the first Kunitz domain of TFPI (TFPIK1(-/-)) rescued with a human TFPI transgene. Pneumonia was induced by intranasal inoculation with S. pneumoniae and samples were obtained at 6, 24 and 48 hours after infection. Anti-TFPI reduced TFPI activity by ~50 %. Homozygous lowTFPI mice and heterozygous controls had ~10 % and ~50 % of normal TFPI activity, respectively. TFPI levels did not influence bacterial growth or dissemination. Whereas lung pathology was unaffected in all groups, mice with ~10 % (but not with ~50 %) of TFPI levels displayed elevated lung cytokine and chemokine concentrations 24 hours after infection. None of the groups with low TFPI levels showed an altered procoagulant response in lungs or plasma during pneumonia. These data argue against an important role for endogenous TFPI in the antibacterial, inflammatory and procoagulant response during pneumococcal pneumonia.

Keywords

Coagulation inhibitors - inflammation - lung - bacterial infection - Streptococcus pneumoniae

• References

• 1 Jones RN. et al. Evolving trends in Streptococcus pneumoniae resistance: implications for therapy of community-acquired bacterial pneumonia. Int J Anti-microb Agents 2010; 36: 197-204.
• 2 van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374: 1543-1556.
• 3 Bartlett JG. et al. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347-382.
• 4 Choi G. et al. Antithrombin inhibits bronchoalveolar activation of coagulation and limits lung injury during Streptococcus pneumoniae pneumonia in rats. Crit Care Med 2008; 36: 204-210.
• 5 Gunther A. et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161: 454-462.
• 6 Rijneveld AW. et al. Plasminogen activator inhibitor type-1 deficiency does not influence the outcome of murine pneumococcal pneumonia. Blood 2003; 102: 934-939.
• 7 Rijneveld AW. et al. Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia. Crit Care Med 2006; 34: 1725-1730.
• 8 Levi M. et al. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003; 31 (Suppl. 04) S238-S242.
• 9 Wygrecka M. et al. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99: 494-501.
• 10 van der Poll T. Tissue factor as an initiator of coagulation and inflammation in the lung. Crit Care 2008; 12 (Suppl. 06) S3.
• 11 Crawley JT, Lane DA. The haemostatic role of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2008; 28: 233-242.
• 12 Bastarache JA. et al. Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity. Am J Physiol Lung Cell Mol Physiol 2008; 294: L874-L881.
• 13 de Moerloose P. et al. Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity. Thromb Res 1992; 65: 507-518.
• 14 El Solh AA. et al. Clinical and hemostatic responses to treatment in ventilator-associated pneumonia: role of bacterial pathogens. Crit Care Med 2007; 35: 490-496.
• 15 Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately?. Blood 2009; 114: 2367-2374.
• 16 Massberg S. et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16: 887-896.
• 17 Choi G. et al. Natural anticoagulants limit lipopolysaccharide-induced pulmonary coagulation but not inflammation. Eur Respir J 2007; 30: 423-428.
• 18 Enkhbaatar P. et al. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation. Am J Respir Crit Care Med 2000; 162: 1752-1759.
• 19 Miller DL. et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26: 650-658.
• 20 van den Boogaard FE. et al. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J Thromb Haemost 2011; 09: 122-132.
• 21 Welty-Wolf KE. et al. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons. Am J Respir Crit Care Med 2001; 164: 1988-1996.
• 22 Wunderink RG. et al. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011; 183: 1561-1568.
• 23 Huang ZF. et al. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 1997; 90: 944-951.
• 24 van Zoelen MA. et al. The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 2009; 182: 4349-4356.
• 25 van den Boogaard FE. et al. Mast cells impair host defense during murine Streptococcus pneumoniae pneumonia. J Infect Dis 2014; 210: 1376-1384.
• 26 Schouten M. et al. Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J Infect Dis 2010; 202: 1600-1607.
• 27 Sandset PM. et al. A sensitive assay of extrinsic coagulation pathway inhibitor (EPI) in plasma and plasma fractions. Thromb Res 1987; 47: 389-400.
• 28 Papareddy P. et al. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 2010; 285: 28387-28398.
• 29 Schirm S. et al. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 2009; 199: 1807-1815.
• 30 Camerota AJ. et al. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 1998; 177: 668-676.
• 31 Carr C. et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-137.
• 32 Creasey AA. et al. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 1993; 91: 2850-2860.
• 33 de Jonge E. et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia. Blood 2000; 95: 1124-1129.
• 34 Moons AH. et al. Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees. Thromb Haemost 2002; 88: 627-631.
• 35 Abraham E. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.
• 36 Bastarache JA. et al. The alveolar epithelium can initiate the extrinsic coagulation cascade through expression of tissue factor. Thorax 2007; 62: 608-616.
• 37 Choi G. et al. Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24: 786-789.
• 38 Enkhbaatar P. et al. Recombinant tissue factor pathway inhibitor prevents lipopolysaccharide-induced systemic hypotension in rats by inhibiting excessive production of nitric oxide. Thromb Haemost 2001; 86: 1573-1577.
• 39 Schultz MJ. et al. Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59: 130-135.
• 40 Hoogerwerf JJ. et al. Activation of coagulation and inhibition of fibrinolysis in the human lung on bronchial instillation of lipoteichoic acid and lipopolysaccharide. Crit Care Med 2009; 37: 619-625.
• 41 Bajaj MS. et al. Transcriptional expression of tissue factor pathway inhibitor, thrombomodulin and von Willebrand factor in normal human tissues. Thromb Haemost 1999; 82: 1047-1052.
• 42 Maroney SA. et al. Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad Sci USA 2012; 109: 3927-3931.
• 43 Singh R. et al. Tissue factor pathway inhibitor deficiency enhances neointimal proliferation and formation in a murine model of vascular remodelling. Thromb Haemost 2003; 89: 747-751.
• 44 Rothmeier AS, Ruf W. Protease-activated receptor 2 signaling in inflammation. Semin Immunopathol 2012; 34: 133-149.
• 45 Shpacovitch V. et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008; 83: 1309-1322.
• 46 Taylor FB Jr.. et al. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 1991; 33: 127-134.
• 47 Ahamed J. et al. Regulation of tissue factor-induced signaling by endogenous and recombinant tissue factor pathway inhibitor 1. Blood 2005; 105: 2384-2391.
• 48 Sun H. et al. Reduced thrombin generation increases host susceptibility to group A streptococcal infection. Blood 2009; 113: 1358-1364.
• 49 Loof TG. et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011; 118: 2589-2598.
• 50 Papareddy P. et al. The TFPI-2 derived peptide EDC34 improves outcome of gram-negative sepsis. PLoS Pathog 2013; 09: e1003803.